AMW GmbH Appoints Additional Experts to its Scientific Advisory Board
01 July 2024
Warngau, Germany, July 1, 2024
AMW GmbH today announced the appointment of Prof. Miriam Breunig, Senior Academic Councillor at the University of Regensburg’s Department of Pharmaceutical Technology, and Prof. Karsten Mäder, Professor of…
AMW Again Reports Record Financial Results 2023, CEO Philipp Karbach Becomes Shareholder, Investment Program For Employees Launched
03 June 2024
Warngau, June 3, 2024
AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, today reported financial results for the year ended December 31, 2023. AMW posted a 2023 consolidated record…
AMW Receives Notified Body Opinion by TÜV SÜD for its Leuprorelin Implant in Pre-Filled Syringe
15 May 2024
Warngau, Germany, May 15, 2024
AMW GmbH, a bio-pharmaceutical company specializing in innovative drug delivery systems, announced today that it has received the final Notified Body Opinion (NBO) report for its leuprorelin implant in prefilled…
AMW welcomes Ilse Aigner, President of the Bavarian State Parliament, at the Warngau site to share a success story
11 April 2024
Warngau, Germany, April 11, 2024
AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, was delighted to welcome today the President of the Bavarian State Parliament, Ilse Aigner, to its…
AMW Further Strengthens Executive Leadership Team by Appointing Dr. Joerg Serafimov as Chief Business Officer
09 January 2024
Warngau, January 9, 2024
AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that Dr. Joerg Serafimov has been appointed to the newly created role as Chief Business Officer…
AMW expands management team for strategic expansion course
28 November 2023
Sebastian Herzog as Chief Operating Officer responsible for Production, Quality, Supply Chain, Engineering, Operational Excellence and Logistics
Finance and IT under the new management of Matthias Dittmer
Warngau, November 28, 2023
…
AMW Receives first Notified Body Opinion by TÜV SÜD and Lays the Foundation for Further Approvals of Goserelin in the EU
09 August 2023
Warngau, August 9, 2023
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has achieved a key milestone in opening new markets within the European Union (EU) and…
AMW reports financial results for fiscal 2022 and updates on corporate performance
11 April 2023
Record sales for fiscal year 2022 of €22.8 million
For the first time operating profitability achieved
Growth strategy secured by long-term financing of up to 30 million euros
Corporate development updates: Philipp Karbach becomes new CEO,…
AMW Appoints Professor Olivia Merkel to the Scientific Advisory Board
07 February 2023
Warngau, February 07, 2023
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced the appointment of Prof. Dr. Olivia Merkel, Professor for Drug Delivery in the Department of…
AMW and SAJA Pharmaceuticals sign license and supply agreement for commercialization of AMW’s goserelin implant
09 January 2023
Warngau and Jeddah, Kingdom of Saudi Arabia, January 9, 2023
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, and SAJA Pharmaceuticals, a leading regional drug manufacturer based in Jeddah, Saudi Arabia, with a…
Further EU Marketing Authorizations for AMW’s Leuprorelin Implant for the Treatment of Hormone-Sensitive Tumors
22 December 2022
Warngau, December 22, 2022
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that its leuprorelin implant has received market authorization in two EU countries. Leuprorelin…
AMW and Mistral sign License and Supply Agreement for Commercialization of AMW’s Goserelin and Leuprorelin implants
25 October 2022
Warngau, Germany, and Coventry, Great Britain, October 25, 2022
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, and Mistral Capital Management Ltd, a pharmaceutical company specialized in…
AMW Strengthens Management Team to Support the Company’s Growth Strategy
10 August 2022
Research & Development, Quality and Human Resources departments under new leadership of seasoned professionals
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it…
Further marketing approvals for AMW’s goserelin implant for the treatment of hormone-sensitive tumors in the EU and Central America
13 July 2022
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, announced today that its proprietary goserelin implant has received two additional marketing approvals in one country each in the European Union and Central…
AMW and AdhexPharma announce strategic partnership for transdermal delivery systems
09 November 2021
09.11.2021, Warngau / Chenôve
Strategic partnership in the field of transdermal delivery systems (TDS)
AMW to focus on its TDS development expertise and to broaden its pipeline on biodegradable slow-release implants
AdhexPharma to focus on TDS…
AMW signs license and supply agreements for the commercialization of its goserelin and leuprorelin implants in Israel
19 October 2021
-AMW grants your license to an undisclosed partner for the commercialization of its goserelin and leuprorelin implants in Israel -Increasing the availability of goserelin and leuprorelin for patients suffering from prostate cancer and breast…
AMW signs License and Supply Agreement for Commercialization of Goserelin Implant in a LATAM Country
22 May 2021
AMW grants license to undisclosed partner for commercialization of its goserelin implant in a LATAM country
Strengthening of availability of goserelin for patients suffering from prostate and breast cancer, as well as other indications as per…
AMW GmbH expands management team and appoints Dr. Konstantin Petropoulos as Chief Executive Officer
15 March 2021
Warngau, 15 March 2021
AMW GmbH announced today that Dr. Konstantin Petropoulos has been appointed Chief Executive Officer (CEO) effective March 15, 2021 This expands Dr. Friedrich Tegel and Philipp Karbach to the existing management team.
Dr.…
EMPLOYEES OF AMW DONATE THE PROCEEDS OF THE TOMBOLA IN THE AMOUNT OF 500 EURO
11 March 2021
Employees of AMW GmbH, a globally active pharmaceutical company based in Warngau, donate the proceeds from a tombola to Holzkirchen. The money was deliberately intended to benefit those in need here on the spot and so the choice was made on…
A thank you for the employees and region
29 December 2020
Santas deliver gifts by truck to the home office
First no company outing, then no Christmas party. Corona has also ruined beautiful traditions at the pharmaceutical developer AMW from Warngau. However, the company has created a replacement. Monday…
Expansion of the partnership between AMW and Zentiva for Western Europe
02 November 2020
Zentiva will include the leuprorelin implant to its portfolio for selected markets in Western Europe. This implant is another successful product of AMW, developed and produced by AMW The leuprorelin implant for the treatment of prostate cancer…
AMW GmbH realigns management
01 May 2020
Dr. Wilfried Fischer, founding shareholder of AMW, has retired from the management board.
He will remain associated with the company as an important shareholder. His areas of responsibility will be taken over by the previous Co-Managing Directors…
AMW GmbH from Warngau continues to grow and establishes an advisory board
26 December 2019
December 2019
Meanwhile more than 100 employees are employed at the pharmaceutical companyin Warngau. The specialy pharmaceuticalwas able to develop a generic drug for the contraception ring Nuvaring of MSD to market maturityin addition to the…
Brussels, 21 December 2017: Investment Plan for Europe: EIB lends to AMW GmbH in Warngau
21 December 2017
Press release
Brussels, 21 December 2017
Investment Plan for Europe: EIB lends to AMW GmbH in Warngau
The European Investment Bank (EIB) is providing EUR 25 million to AMW GmbH (AMW). AMW is a specialist pharmaceutical company that specializes in…
Endomedica GmbH, our wholly owned subsidiary based in Halle, was able to present itself to a wide audience including well-known pharmaceutical companies and investors from the fields of biotechnology and medical technology at the Health Innovation Summit
11 July 2017
July 2017
The event took place simultaneously as a webinar in Munich, Tokyo and Silicon Valley and allowed discussion rounds after the presentation.
On 22 June 2017, the AMW received a high visit from the Bavarian Minister of Economic Affairs and Deputy Prime Minister of the Free State of Bavaria.
22 June 2017
June 2017
In this context, AMW was able to present itself as the largest training company in Warngau. After a one hour meeting with AMW founder, Dr. Fischer and his management board as well as a subsequent tour through the manufacturing site, Miss…
Specialty pharmaceutical company AMW takes big steps
09 November 2016
Warngau – AMW GmbH, founded in 2008 and based in Warngau south of Munich, is a dynamically growing specialty pharmaceutical company with bright prospects. The company develops and sells transdermal systems, i.e. active ingredients that enter the…
Chamber of Commerce Munich and Upper Bavaria: Training company 2016
06 February 2016
This company ensures quality through vocational training in several occupations.
For the biodegradable goserelin implants 3.6 mg and 10.8 mg developed by AMW GmbH and clinically tested, the national approval was obtained today as part of a DCP procedure.
04 November 2015
The products are characterized by innovative applicators. Handling is easier, misapplications and painful injections are avoided.
BfArM approvals from DCP procedure for Rivastigmin patches granted for Germany, Austria, Romania, Sweden, Slovakia and the Czech Republic
28 August 2015
On August 28, 2015, the BfArM received approvals from the DCP process for rivastigmine patches in the dosages 4.6 mg / 24 h and 9.5 mg / 24 h for the countries Germany, Austria, Romania, Sweden, Slovakia and the Czech Republic granted.
Successful financing round for pharmaceutical company AMW
06 September 2014
AMW GmbH (Arzneimittelwerk Warngau) has secured follow-up financing to advance the development and marketing process for its drug delivery systems. BayBG Bayerische Beteiligungsgesellschaft, UnternehmerTUM Fund and IBG Beteiligungsgesellschaft are…
AMW GmbH announces that another round of financing has been concluded with the existing shareholders.
26 February 2014
AMW GmbH announces that another round of financing has been concluded with the existing shareholders. The funds are used to strengthen further growth and the development of innovative products. Dr. Wilfried Fischer, managing director of AMW GmbH,…
In January 2014, AMW GmbH was able to conclude a semi-exclusive license and supply contract for its biodegradable goserelin implants with a multinational pharmaceutical company.
02 January 2014
The contract applies to Southeast Asia, including China, Eastern Europe, Russia and some Western European countries.
The agreements contain down payment payments of up to € 10 million, license payments in the double-digit percentage range, and an…
AMW GmbH has been successfully certified by Tüv Süd to EN ISO 13485: 2012/AC: 2012
07 October 2013
No.ISO certificate: Q21-1.13.07.84140.001
Validity: from 07.10.2013 to 06.10.2016
Scope: Manufacture, quality control, quality assurance and distribution of medical devices in plaster form
Applied standard(s):
EN ISO 13485: 2012/AC: 2012
…
Obtaining unrestricted manufacturing permission for transdermal systems and drug implants
02 May 2011
Authority: Government of Upper Bavaria
Type of inspection: General GMP inspection in accordance with Section 64 of the Medicinal Products Act (AMG), the provisions of the Medicinal Products and Active Substances Manufacturing Ordinance (AMWHV) and…
Obtaining manufacturing permission for sterile products
01 July 2009
Authority: Government of Upper Bavaria
Type of inspection: General GMP inspection in accordance with Section 64 of the German Medicines Act (AMG), the provisions of the German Medicines and Drug Manufacturing Ordinance (AMWHV) and the EC-GMP Guide…